Clinical Trials Campaign Launches to Boost Research in Greece

—

in

Clinical trials are back in the spotlight—this time with a new national awareness campaign aimed at accelerating their development across Greece. Led by the Alliance for Advancing the Value of Clinical Trials, the initiative was officially unveiled at a press conference held at the Ministry of Health on May 20, 2026—coinciding with World Clinical Trials Day.

A Growing Momentum

Since 2019, Greek health authorities have pursued sustained policy initiatives to remove longstanding barriers that delayed trial approvals and implementation. Early results are promising: applications for clinical trials rose from 158 in 2019 to 183 in 2023, then to 212 in 2024, and reached 272 in 2025—a trajectory officials describe as just the beginning.

Prioritizing Patient Access and Innovation

Health Minister Adonis Georgiadis emphasized that clinical trials are a top priority for the ministry—not only because they provide patients faster access to cutting-edge therapies, but also because they can be life-saving. “For us, clinical trials are not on autopilot—they’re something we actively care about,” he stated.

Beyond patient benefits, the trials contribute to strengthening Greece’s healthcare expertise, improving service delivery, attracting investment, and generating new jobs—offering measurable gains for both the National Healthcare System (ESY) and the broader economy.

What Changed?

Lilian Bildiridi, General Secretary of Health Services, underscored that clinical trials represent a vital indicator of scientific, social, and economic progress. Since 2019, Greece has treated them as a strategic national goal—starting with the establishment of the Working Group for the Promotion of Clinical Trials and Biomedical Research. Its findings identified key bottlenecks: slow regulatory review timelines, insufficient incentives for researchers and hospitals, and low participation rates.

A major recent step was the adoption of a Joint Ministerial Decision (JMD) earlier this year, setting strict time limits for reviewing trial applications submitted to the Hellenic Organization for Medicines (EOF). Where approval once took three to four months, it now takes just a few weeks—from submission to study launch.

New Initiatives Underway

“Challenges remain—and new initiatives are already underway,” said Bildiridi. Among them are the gradual establishment of dedicated clinical trial units within public hospitals and the creation of the National Registry of Biomedical Research—a centralized platform to support transparency, coordination, and long-term planning.